In addition, silencing of the APRIL receptor (TNFRSF13B) in the TNBC cell line induced significant cell death, indicating the APRIL system as a potential therapeutic target for the TNBC [48]. APRIL serum level was higher in patients with brain tumors in comparison to healthy individuals [49]...